Structural Heart Disease Highlights: A close look at the TRILUMINATE trial | Key research in interventional cardiology

Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

SCAI President Sunil Rao, MD, spoke with us about some of the key interventional cardiology studies presented at ACC.23 in New Orleans. 

The newly approved valve is the latest addition to Abbott’s Epic surgical valve platform.

After its initial release was limited to certain customers, the new-look catheter is now available in four different sizes throughout the United States.

One of the new recommendations is to conduct baseline imaging with TEE or cardiac CT.

Early SVD has been reported in these devices, particularly three to four years after implantation. According to the FDA, this has resulted in surgical replacement procedures and transcatheter valve-in-valve interventions. In some cases, the patient died.

The device, which gained FDA approval in 2021, was part of a voluntary recall in 2022 due to stability concerns. Medtronic worked with the FDA to address the issue, and the Harmony TPV is once again available throughout the United States.